Orlistat: weight lost at cost of HIV rebound | Zendy

Cristina Gervasoni | Zendy; Dario Cattaneo | Zendy; Valentina Di Cristo | Zendy; Simone Castoldi | Zendy; Elena Gervasi | Zendy; Emilio Clementi | Zendy; Agostino Riva | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Orlistat: weight lost at cost of HIV rebound

Author(s) -

Cristina Gervasoni,

Dario Cattaneo,

Valentina Di Cristo,

Simone Castoldi,

Elena Gervasi,

Emilio Clementi,

Agostino Riva

Publication year - 2016

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkw033

Subject(s) - orlistat , human immunodeficiency virus (hiv) , medicine , weight loss , virology , obesity

s of the Twelfth Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA, 2005. Abstract A646. Foundation for Retrovirology and Human Health, Alexandria, VA, USA. 8 Evans S, Michael R, Wells H et al. Drug interaction in a renal transplant patient: cyclosporin-Neoral and orlistat. Am J Kidney Dis 2003; 41: 493–6. 9 Zhi J, Moore R, Kanitra L et al. Effects of orlistat, a lipase inhibitor, on the pharmacokinetics of three highly lipophilic drugs (amiodarone, fluoxetine, and simvastatin) in healthy volunteers. J Clin Pharmacol

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research